{"version":"1.0","type":"card","id":"cf25c1df-d569-4b4b-871e-93890310d64b","url":"https://stacklist.com/card/cf25c1df-d569-4b4b-871e-93890310d64b","title":"They Came to America With One Backpack Each. Now They're Reprogramming How We Fight Cancer.","source_url":"https://unshackledvc.substack.com/p/they-escaped-one-of-the-worlds-most","note":"Reprogram Biosciences is announcing the close of its seed round, bringing total capital raised to $6 million since founding. This page discusses the innovative approaches being taken to combat cancer through new bioscience technologies.","image":{"url":"https://ucarecdn.com/5b558570-174e-428a-b38c-abe091560275/","alt":"They Came to America With One Backpack Each. Now They're Reprogramming How We Fight Cancer.","width":1254,"height":1254},"stack":{"id":"f8553b69-ce7a-48b8-ad46-b884c9a590e7","title":"Signals Served #013 — The Specific Get Funded","url":"https://stacklist.com/c/finance/stack/f8553b69-ce7a-48b8-ad46-b884c9a590e7"},"created_at":"2026-06-05T17:30:08.220Z","updated_at":null,"aco":{"summary":"Reprogram Biosciences, founded by immigrant scientists Rustam Esanov and Eziz Kuliyev, has closed its $6 million seed round to develop an mRNA-based therapy that reprograms cancerous cells into antigen-presenting cells to fight solid tumors. The company's off-the-shelf approach uses proprietary transcription factors delivered directly into tumors, backed by investors including Unshackled Ventures, 1517 Fund, and Narya Capital.","tags":["biotech","cancer-immunotherapy","cell-reprogramming","seed-funding","mrna","solid-tumors","startup"],"key_entities":[{"name":"Reprogram Biosciences","type":"organization","confidence":0.99},{"name":"Rustam Esanov","type":"person","confidence":0.99},{"name":"Eziz Kuliyev","type":"person","confidence":0.99},{"name":"Unshackled Ventures","type":"organization","confidence":0.97},{"name":"Manan Mehta","type":"person","confidence":0.9},{"name":"1517 Fund","type":"organization","confidence":0.95},{"name":"Narya Capital","type":"organization","confidence":0.95},{"name":"GSK","type":"organization","confidence":0.93},{"name":"CellRecodeX","type":"technology","confidence":0.95},{"name":"mRNA delivery","type":"technology","confidence":0.92},{"name":"cell reprogramming","type":"concept","confidence":0.97},{"name":"antigen-presenting cells","type":"concept","confidence":0.93},{"name":"abscopal effect","type":"concept","confidence":0.88},{"name":"Turkmenistan","type":"location","confidence":0.95},{"name":"Moderna","type":"organization","confidence":0.85},{"name":"UCSD","type":"organization","confidence":0.88}],"classification":"memo","language":"en","confidence":0.85,"provenance":{"model":"claude-opus-4-6","tool":"@stacklist/mcp-server@2.0.0","confidence":0.85,"timestamp":"2026-06-05T17:30:18.122Z"},"token_counts":{"approximate":1853,"cl100k":1571},"content_hash":"sha256:6f89df5b6335120609d49f73c521dfb593d305d07cc68b5dc6aafad2e69ab21a","acp_version":"0.2","body_available":true,"body_tokens":1853,"visibility":"public","agent_accessible":true,"status":"final"},"_links":{"self":"/api/public/card/cf25c1df-d569-4b4b-871e-93890310d64b.json","html":"https://stacklist.com/card/cf25c1df-d569-4b4b-871e-93890310d64b","md":"/api/public/card/cf25c1df-d569-4b4b-871e-93890310d64b.md","stack_json":"/api/public/stack/f8553b69-ce7a-48b8-ad46-b884c9a590e7.json"}}